openPR Logo
Press release

Biosimilars Market | Key players in the Biosimilars Market include Pfizer, Sandoz International,Teva Pharmaceuticals, Amgen , Biocon, Dr. Reddy's Laboratories , Celltrion and Samsung Biologics.

05-31-2019 05:10 PM CET | Health & Medicine

Press release from: MarketsandMarkets.com

Biosimilars Market | Key players in the Biosimilars Market

According to a new market research report "Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 23.63 Billion by 2023 from USD 5.95 Billion in 2018, at a CAGR of 31.7%.

Browse 176 market data Tables and 37 Figures spread through 181 Pages and in-depth TOC on "Biosimilars Market"
https://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html?utm_source=OpenPR&utm_medium=Paid

Early buyers will receive 10% customization on this report

The factors expected to drive the growth of this market include the increasing demand for biosimilar drugs due to their cost-effectiveness and the rising incidence of chronic diseases.

Recombinant glycosylated proteins are expected to be accounted for the largest market share in 2018

By product, the biosimilar market is classified into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. Recombinant glycosylated proteins are expected to hold the largest share of the market during the forecast period. The key factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins and presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products.

Ask for PDF Brochure : https://www.marketsandmarkets.com/pdfdownload.asp?id=40&utm_source=OpenPR&utm_medium=Paid

The in-house manufacturing segment held the largest share of the market in 2017

By type of manufacturing, the market is segmented into in-house manufacturing and contract manufacturing. In-house manufacturing accounted for the largest share of the global Biosimilars Market in 2017. The growing demand for cost-effective biosimilar products owing to the rising incidence of various diseases is driving the growth of the in-house manufacturing segment

Europe accounted for the largest share of the global Biosimilars Market in 2017

Europe accounted for largest share of the global Biosimilars Market in 2017, followed by Asia. Growth in this regional market is expected to be driven by patent expiry of biologic products & the launch of new biosimilars, raising incidence of chronic disorders, and the emergence of new market participants

Request For Sample Report :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=40&utm_source=OpenPR&utm_medium=Paid

Key players in the Biosimilars Market include Pfizer (US), Sandoz International (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy's Laboratories (India), Celltrion (South Korea), and Samsung Biologics (South Korea).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: www.marketsandmarkets.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biosimilars Market | Key players in the Biosimilars Market include Pfizer, Sandoz International,Teva Pharmaceuticals, Amgen , Biocon, Dr. Reddy's Laboratories , Celltrion and Samsung Biologics. here

News-ID: 1761267 • Views:

More Releases from MarketsandMarkets.com

Concrete Surface Retarders Market worth $89.4 million by 2023 : Major Players are Sika (Switzerland), BASF (Germany), MAPEI (Italy), GCP Applied Technologies (US), CEMEX (Mexico), W. R. Meadows (US)
Concrete Surface Retarders Market worth $89.4 million by 2023 : Major Players ar …
The report "Concrete Surface Retarders Market by Raw Material (Organic Agents and Inorganic Agents), Type (Water-based and Solvent-based), Application (Residential and Commercial), and Region (North America, Europe, Asia Pacific) - Global Forecast to 2023", The concrete surface retarders market is projected to grow from USD 72.7 million in 2018 to USD 89.4 million by 2023, at a CAGR of 4.2% between 2018 and 2023. Increase in urban population, demand for
Precast Concrete Market worth $174.1 billion by 2025 | Major Players are Lafarge …
The report "Precast Concrete Market by Element (Columns & Beams, Floors & Roofs, Girders, Walls & Barriers, Utility Vaults, Pipes, Paving Slabs), Construction Type, End-use Sector (Residential, Non-residential) - Global Forecast to 2025" The global precast concrete market size is projected to grow from USD 130.6 billion in 2020 to USD 174.1 billion by 2025, at a CAGR of 5.9% from 2020 to 2025. The market is projected to grow
Fire Stopping Materials Market worth $2.4 billion by 2026 : Major Players are Hi …
The report "Fire Stopping Materials Market by Type (Sealants, Mortar, Boards, Putty &Putty Pads, Cast-in Devices), by Application (Electrical, Mechanical, Plumbing), End-Use (Commercial, Industrial & Residential), and Region - Global Forecast to 2026" MarketsandMarkets: The fire stopping materials market is projected to reach USD 2.4 billion by 2026, at a CAGR of 11.6% from USD 1.4 billion in 2021. Fire stopping is a fire protection system for sealings of any
Earthen Plasters Market worth $103 million by 2026 : Leading players are American Clay Enterprises LLC (US), Clayworks (India), Claytech Baustoffe Aus Lehm (UK), Conluto (Germany) and Clay.lt (Lithuania)
Earthen Plasters Market worth $103 million by 2026 : Leading players are America …
The report "Earthen Plasters Market by Type (Iron, Calcium, Magnesium, Silicates, Aluminium), Application (Walls, Roofs, Masonry, Agriculture,) and Region (APAC, North America, Europe, MEA & South America) - Global Forecast to 2026", size is expected to grow from USD 86 million in 2021 to USD 103 million by 2026, at a CAGR of 3.5% during the forecast period. The driving factors for the earthen plasters market is the advantages of

All 5 Releases


More Releases for Biosimilars

Global Biosimilars Market 2021-2028 | Price Advantage of Biosimilars Over Biolog …
The global Biosimilars market focuses on encompassing major statistical evidence for the Biosimilars industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition, the Biosimilars study also shifts its attention with an in-depth
Growth of the Biosimilars Market Is Mainly Driven by Increasing Number of Approv …
A biosimilar is a biologic medical product that is similar to another already approved biological medicine, in terms of quality, safety, and efficacy. Biosimilars are a class of therapeutic drugs that provide additional treatment options and help reduce healthcare costs. Thus, there is an increasing demand for biosimilar drugs due to increasing prevalence of autoimmune diseases, key factor driving the growth of the biosimilars market. According to the National Stem
Global Oncology Biosimilars Market | Global Oncology Biosimilars Industry | Onco …
The oncology biosimilars market involves of sales of medicine and drug interrelated products for cancer treatment. Biosimilars are pharmaceuticals which are produced using cell lines and are fashionable to the manufacturer. The manufacturing of such cell line processes is a multipart and time-consuming procedure. According to the report analysis, ‘Oncology Biosimilars Market Global Report 2020-30’ states that the worldwide oncology biosimilars market was worth USD 2990.34 million in 2019. It is
Global Biosimilars Market | Global Biosimilars Industry | Global Biosimilars Mar …
The biosimilars market involves of sales of biosimilars and associated services that are cast-off to treat chronic sicknesses such as diabetes, arthritis, and cancer. The Biosimilars are pharmaceuticals that are produced using cell lines and offers no clinical difference as linked to biologics. The Biosimilars are made once the patent of biologics is deceased. According to the report analysis, ‘Biosimilars Market Global Report 2020-30’ states that the worldwide biosimilars market was
Global Oral Biologics and Biosimilars Market | Global Oral Biologics and Biosimi …
The oral biologics and biosimilar market contain of sales of oral biologics and biosimilar products and associated services utilized to treat chronic syndromes such as diabetes, arthritis, cancer. Biologics are drugs completed from living cells using exceedingly complex technology while biosimilars are generated to function similarly to biologics but are not matching to biologics. Biosimilars offer energetic properties as any licensed biologic drug. The oral biologics and biosimilar market encompass
Insulin Biosimilars Market, by Biosimilar Type Rapid-acting Biosimilars, Long-ac …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million